Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline in Autism Spectrum Disorder
NCT04031755Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Apr 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of minocycline in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Subject weight at 2 years, Aberrant Behavior at 2 years and 1 more. Started Apr 2019; status: completed.
02
Drugs
minocycline
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04031755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04031755.